Silexion Therapeutics Bolsa (NASDAQ: SLXN)

Últimas noticias sobre Silexion Therapeutics (NASDAQ:SLXN) Bolsa

Silexion Therapeutics

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACLS

AMKR

BHAT

BNAI

FLNC

GNPX

HLIT

LIXT

LSCC

NLSP

OCEA

PRLD

SGRY

SLQT

SLXN

TANH

VSTE

Lattice Semiconductor sorprende con un alza del 14,7% en el premercado. Descubre qué otras acciones están en movimiento.

Acciones de Lattice Semiconductor (LSCC) suben un 15%; 20 acciones que se mueven en el premercado

APPS

AVGR

BBAI

COHR

DGLY

FORM

MBRX

MTRX

PTIX

RANI

RXRX

SBET

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SWKS

Coherent sorprende con sus resultados trimestrales y dispara sus acciones un 15,5%. ¿Qué otras empresas se mueven en el premercado de EE.UU.?

Acciones de Coherent (COHR) se disparan un 15%; 20 acciones que se mueven en el premercado de EE.UU.

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

OFIX

RNGR

TSLA

VREX

XFOR

Meta sube en la preapertura tras superar expectativas. Descubre qué otras acciones están registrando fuertes movimientos hoy.

Acciones de Meta Platforms (META) están cotizando al alza; 20 acciones que se mueven en el premercado de EE.UU.

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics Corp

Words matter—especially when you have nearly 400 million subscribers and every sentence you say can be clipped, twisted, and turned into a headline. MrBeast, <a href="https://www.benzinga.com/media/25/02/43996522/mrbeast-lost-millions-on-amazons-beast-games-now-hes-looking-to-raise-hundreds-of-millions-to-take-his-brand-to-the-next-level">aka Jimmy Donaldson</a>, woke up to find that one of his interviews had been reduced to a quote he says he never actually said: "Life is so much easier when you're broke."
The quote made its rounds after a post from Kotaku, which slapped the line front and center on a viral article and Facebook post. Cue outrage, confusion, and a flurry of angry replies—including one vile, hate-filled message shown in a screenshot MrBeast shared on X last month.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
But here's the thing: he never said it. At least not like that.
"A news site lied and said I said ‘life is so much easier when you're broke' which I didn't say," <a href="https://x.com/MrBeast/status/1895849826979651873">MrBeast posted to X on March 1</a>. "Now I'm waking up to millions of people believing the lie and hating me. Being famous is so much fun," he added, with a thumbs-up emoji so dry you could sand wood with it.
In a <a href="https://x.com/MrBeast/status/1895852639898005977">follow-up post that same day</a>, he continued: "Here's what I actually said, such a shame that only a small % of the people that saw the slanderous article will see this. Sigh."
So, what did he actually say?
In the clip, MrBeast begins, "Life is so much easier…" then pauses before continuing, "Bro, if you don't travel constantly, life is so much easier." It wasn't about being broke. It was about being burnt out.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
The full interview dove into his 15-hour workdays, health struggles, and the pressure that comes with being one of the <a href="https://www.benzinga.com/news/25/04/44794639/ironically-because-of-all-the-new-tariffs-its-now-way-cheaper-to-make-our-chocolate-bars-outside-the-us-says-mrbeast">most recognizable faces on the internet</a>. He even mentioned he has less than a million dollars in his bank account—hardly the typical millionaire mindset headline bait would suggest.
Kotaku did go back and update the headline. The article now reads: "MrBeast: Life Is ‘Easy' When You ‘Wake Up In Your Own Bed' And ‘Work 15 Hours' (Update)"—a noticeably different message.
Still, the damage had been done. The original post, amplified by Kotaku's huge reach, spread like wildfire. A flood of replies—some genuinely upset, others just trolling—rolled in before the correction.
The whole thing is a sharp reminder that when you're internet-famous, one misquote can shape public perception in seconds. And getting the truth out? That's the part that's never quite as viral.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li>With high-demand properties in the Midwest, Bam Capital has delivered 2.46x equity multiples in just over 3 years. No losses. No missed payments. <a href="https://www.benzinga.com/money/investing-in-the-midwest-why-multifamily-real-estate-is-a-winning-strategy">Learn more about becoming an investor today</a>. </li>
</ul>
Image: Shutterstock

Personal Finance

'Now Millions Hate Me' — MrBeast Says Article Twisted His Words, Falsely Quoted Him as Saying 'Life's Easier When You're Broke'

Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) has outperformed the market over the past 10 years by 1.48% on an annualized basis producing an average annual return of 11.21%. Currently, Allison Transmission has a market capitalization of $7.62 billion. 
Buying $100 In ALSN: If an investor had bought $100 of ALSN stock 10 years ago, it would be worth $278.57 today based on a price of $89.42 for ALSN at the time of writing.
<h3>Allison Transmission's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745447421_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALSN

Here's How Much You Would Have Made Owning Allison Transmission Stock In The Last 10 Years

<a href="https://www.benzinga.com/topic/chinese-stocks" target="_blank" rel="noreferrer noopener">U.S.-listed China stocks</a> rose on Wednesday, spurred by optimism over Beijing&#8217;s softening trade tensions with Washington following the latest comments from the Trump administration.
Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), and&nbsp;Baidu, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) maintained their rally Wednesday.
Electric vehicle companies, including&nbsp;NIO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>),&nbsp;Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), and&nbsp;XPeng Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), also noted strong upward momentum.
President Donald Trump hinted at a substantial reduction in tariff rates as he proposed to treat China fairly as its trading partner, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-23/chinese-stocks-in-hong-kong-rally-on-bets-trade-tensions-to-ease?sref=TBDibEcD" rel="noreferrer noopener">reports</a> on Wednesday.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44874701/temu-and-shein-to-raise-prices-amid-us-tariffs-slash-ad-spend-on-apple-meta" rel="noreferrer noopener">Temu And Shein To Raise Prices Amid US Tariffs, Slash Ad Spend On Apple, Meta</a>
On Tuesday, Treasury Secretary Scott Bessent&nbsp;acknowledged during an investor summit the impracticability and mutual challenges of a tariff war with China.
Trump&#8217;s&nbsp;hint of retaining Federal Reserve Chair Jerome Powell also buoyed the spirits.
Additionally, Chinese trade flows <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44935325/why-are-us-listed-chinese-stocks-trading-higher-on-tuesday" rel="noreferrer noopener">exhibited momentum in</a> April despite President Donald Trump&#8217;s tariff war against&nbsp;its trading partners.
Trump&#8217;s tariff relief on electronic products and pause of reciprocal tariffs against most countries posed a tailwind.
Separate reports indicated that China&#8217;s&nbsp;Xi Jinping&nbsp;is eyeing Europe as a key trading partner as it proposes to tap the&nbsp;strained U.S.-EU relations.
Investors can gain exposure to the stock rally via China ETFs trading in the U.S., including iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) and KraneShares Trust KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>).
Price Action: BABA stock gained 2.57% on Wednesday. PDD was up 2.08, BIDU up 2.88%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44895667/alibabas-ai-powered-cancer-detection-tool-wins-fda-breakthrough-status" target="_blank" rel="noreferrer noopener">Alibaba&#8217;s AI-Powered Cancer Detection Tool Wins FDA Breakthrough Status</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Tech

BABA

BIDU

KWEB

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XPEV

US-Listed China Stocks Surge As Trump Hints At Tariff Cuts and Softening Trade Tensions

Shares of Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) spiked in Wednesday&#8217;s after-hours session before pulling back. Here&#8217;s a look at <a href="https://www.benzinga.com/topic/automakers">what&#8217;s going on</a>.
What Happened: According to a Financial Times <a href="https://www.ft.com/content/fa0f6749-729e-41ca-917b-7b534041f6f8">report</a>, President Donald Trump is expected to relax tariffs on automakers following &#8220;intense&#8221; lobbying from industry executives in recent weeks. 
The report, which cites two people with knowledge of the matter, indicates Trump could exempt car parts, steel and aluminum from tariffs imposed on imports from China.
Automakers will reportedly still face 25% duties on all imports of foreign-made cars, as well as separate 25% tariffs on parts set to go into effect on May 3.
The news comes after various executives from the auto industry raised concerns that tariffs would drive up vehicle prices, force job losses and impact supply chains.
Related Link: <a href="https://www.benzinga.com/25/04/44963440/tesla-takedown-says-protests-are-working-hitting-ev-company-where-it-hurts-the-companys-bottom-line">Tesla Takedown Says Protests Are Working: Hitting Where It Hurts, &#8216;The Company&#8217;s Bottom Line&#8217;</a>
Stellantis chair John Elkann reportedly warned last week that the automobile industry was being &#8220;put at risk&#8221; due to the Trump administration&#8217;s trade policies. Another executive in the space reportedly said that tariffs were jeopardizing the health of the entire industry. 
Trump slapped sweeping reciprocal tariffs on a slew of nations at the beginning of the month, before announcing a 90-day pause for most countries. Trade partners still face 10% baseline tariffs during the 90-day pause period. 
Shares of Ford, GM and Stellantis all jumped in extended trading Wednesday before pulling back. Ford traded up to around $10, but was down 0.36% after hours, trading at $9.73 at last check. 
GM shares traded up to around the $48.40 level, but were down 0.70% after the close, trading at $45.50 at the time of publication. Stellantis was the only automaker holding onto gains, last up 0.95% after hours, trading at $9.01. Stellantis traded as high as $9.30 in after-hours trading Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44948841/trump-economic-approval-rating-drops-to-37-as-market-selloff-erodes-public-support-poll">Trump Economic Approval Rating Drops To 37% As Market Selloff Erodes Public Support: Poll</a></li>
</ul>
Photo: Tada Images/Shutterstock.

Global

After-Hours Center

STLA

Auto Stocks See Brief Spike In After-Hours Trading Wednesday As Trump Plans To Ease Tariffs On Automakers

Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) has outperformed the market over the past 20 years by 3.7% on an annualized basis producing an average annual return of 11.63%. Currently, Kroger has a market capitalization of $51.81 billion. 
Buying $1000 In KR: If an investor had bought $1000 of KR stock 20 years ago, it would be worth $9,131.26 today based on a price of $71.60 for KR at the time of writing.
<h3>Kroger's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745446511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Kroger 20 Years Ago Would Be Worth Today

Citizens &amp; Northern (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZNC#NASDAQ">CZNC</a>) reported quarterly earnings of $0.41 per share which missed the analyst consensus estimate of $0.44 by 6.82 percent. This is a 17.14 percent increase over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $26.98 million which missed the analyst consensus estimate of $27.70 million by 2.59 percent. This is a 4.93 percent increase over sales of $25.72 million the same period last year.

Earnings

Earnings Misses

CZNC

Citizens & Northern Q1 EPS $0.41 Misses $0.44 Estimate, Sales $26.98M Miss $27.70M Estimate

Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) reported first-quarter financial results after the market close on Wednesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/quote/LUV">of the report</a>.
<ul>
<li>Q1 Revenue: $6.43 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $6.40 billion</li>
</ul>
<ul>
<li>Q1 EPS: Loss of 13 cents, versus estimates for a loss of 18 cents</li>
</ul>
First-quarter operating revenue increased 1.6% year-over-year. The company said passenger revenue increased 1.7% year-over-year. Revenue per available seat mile (RASM) increased 3.5% year-over-year. Growth was primarily driven by yield improvements from revenue management actions and capacity moderation.
The company ended the quarter $8.3 billion in cash, cash equivalents and short-term investments, resulting in a net cash position of $1.6 billion, which includes debt. Southwest returned $857 million to shareholders in the first quarter in dividends and share repurchases and said it expects to repurchase the remaining $1.5 billion under its buyback by the end of July. 
&#8220;While the broader economic environment has been dynamic, we remain focused on executing our transformational plan. On costs, we beat our previously adjusted&nbsp;guidance&nbsp;and are on track to achieve the increased cost reduction plan targets announced last month. We ran a stellar operation in&nbsp;first quarter, leading the industry in&nbsp;ontime performance and improving on almost every operating metric, year-over-year,&#8221; said Bob Jordan, president and CEO of Southwest Airlines.
Don&#8217;t Miss: <a href="https://www.benzinga.com/general/gaming/25/04/44966332/las-vegas-sands-stock-down-slightly-after-mixed-q1-results-eps-beat-revenue-misses">Las Vegas Sands Stock Down Slightly After Mixed Q1 Results: EPS Beat, Revenue Misses</a>
Outlook: Southwest Airlines pulled its full-year 2025 and 2026 EBIT guidance, citing &#8220;current macroeconomic uncertainty.&#8221;
The company said it expects second-quarter unit revenues to be flat to down&nbsp;4%. Capacity is expected to grow between 1% and 2% year-over-year in the second quarter. Southwest expects cost per available seat mile excluding fuel (CASM-X) to increase 3.5% to 5.5% year-over-year in the second quarter, driven primarily by inflationary pressures.
The company expects full-year 2025 capacity to be up roughly 1%, versus prior expectations of 1% to 2%. Southwest continues to expect 2025 capital spending to be in the range of&nbsp;$2.5 billion&nbsp;to&nbsp;$3 billion.
&#8220;We expect to introduce basic economy and bag fees for most fare products next month and remain on track to begin selling assigned and extra legroom seats in&nbsp;third quarter&nbsp;2025 for operation beginning in&nbsp;first quarter&nbsp;of next year,&#8221; Jordan said. 
Southwest Airlines executives will further discuss the quarter on a call with investors and analysts at 12:30 p.m. ET Thursday afternoon. 
LUV Price Action: <a href="http://benzinga.com/quote/LUV">Southwest Airlines shares</a> were down after-hours 3.61% at $24.60 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Southwest Airlines.

Guidance

Travel

Southwest Airlines Tosses Out Profit Guidance Amid 'Macroeconomic Uncertainty,' Shares Slide Despite Better-Than-Expected Q1 Results

First Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBNC#NASDAQ">FBNC</a>) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.78 by 7.69 percent. This is a 37.7 percent increase over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $105.78 million which beat the analyst consensus estimate of $105.37 million by 0.39 percent. This is a 14.77 percent increase over sales of $92.17 million the same period last year.

Earnings Beats

First Bancorp Q1 Adj. EPS $0.84 Beats $0.78 Estimate, Sales $105.78M Beat $105.37M Estimate

D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares are trading higher on Wednesday following the completion of its Advantage2 quantum computer's physical assembly at Davidson Technologies<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44945155/d-wave-and-davidson-technologies-near-installation-completion-of-alabamas-first-on-site-annealing-" rel="noreferrer noopener"> headquarters in Huntsville, Alabama.</a>
This development marks a critical phase in D-Wave's collaboration with Davidson and advances Alabama's position as a key player in the U.S. quantum infrastructure ecosystem.
With physical assembly wrapped up, the system is now undergoing calibration and performance testing to prepare it for secure operational deployment.
Once live, the Advantage2 will become Alabama's first on-premises annealing quantum system, focused on real-world optimization problems in national security and defense applications.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/04/44948932/goldman-sachs-backs-copper-tariff-trade-if-trump-slaps-25-duty-on-us-imports" rel="noreferrer noopener">Goldman Sachs Backs &#8216;Copper Tariff Trade&#8217; If Trump Slaps 25% Duty On US Imports</a>
The installation will be formally unveiled at a private ribbon-cutting ceremony on April 23, with state and federal leaders in attendance alongside executives from both companies.
Dr. Alan Baratz, CEO of D-Wave, emphasized the importance of the system for defense-focused quantum innovation, stating the machine will support the creation of applied quantum solutions in secure environments.
&#8220;The installation of an Advantage2 system will enable Davidson to explore and develop real-world quantum applications — particularly in optimization — for some of the U.S. government&#8217;s most complex problems and then deploy those applications in a secure environment,&#8221; Baratz said.
Dale Moore, president and CEO of Davidson, called the installation a "step-change" in deploying quantum tools for precision defense tasks, underlining the significance of having such technologies onsite to drive mission outcomes.
This milestone is part of a long-term agreement between the two firms, with Davidson investing in research and hybrid quantum-classical approaches for defense-relevant use cases such as space system oversight, autonomous coordination, and logistics optimization.
Tommy Battle, mayor of Huntsville, praised the project for cementing the city's place in the national innovation landscape and broadening its role in advanced tech development for both government and private sectors.
The Advantage2 will complete final testing in the coming weeks, after which it will be operationalized under national security protocols with collaborative initiatives across the defense sector already in planning.
QBTS Price Action: D-Wave Quantum shares are trading higher by 13.60% to $7.10 at publication on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44948499/boeing-stock-jumps-after-q1-2025-results-production-expansion-plans-for-737-and-787" target="_blank" rel="noreferrer noopener">Boeing Clocks 18% Q1 Topline Growth, Plans Production Expansion For 737 And 787</a></li>
</ul>

Equities

General

QBTS

What's Going On With D-Wave Quantum Stock Today?

Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) reported quarterly earnings of $0.67 per share which beat the analyst consensus estimate of $0.64 by 4.69 percent. This is a 3.08 percent increase over earnings of $0.65 per share from the same period last year. The company reported quarterly sales of $491.37 million which beat the analyst consensus estimate of $482.85 million by 1.77 percent. This is a 3.73 percent increase over sales of $473.72 million the same period last year.

COLB

Columbia Banking System Q1 Adj. EPS $0.67 Beats $0.64 Estimate, Sales $491.37M Beat $482.85M Estimate

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) released its first-quarter results after Wednesday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/04/n44964150/viking-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-update"> from the report.&nbsp;</a>
The Details:&nbsp;Viking Therapeutics reported quarterly losses of&nbsp;41 cents&nbsp;per share, which missed the analyst consensus estimate of&nbsp;losses of 34 cents.
The company said the increase in the quarterly net loss was primarily due to the increase in research and development expenses and general and administrative expenses compared to the same period in 2024.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
Research and development expenses were $41.4 million for the first quarter, compared to $24.1 million for the same period in 2024. The increase was primarily due to increased expenses related to manufacturing for the company&#8217;s drug candidates, clinical studies, stock-based compensation and salaries and benefits, partially offset by decreased expenses related to pre-clinical studies.
General and administrative expenses were $14.1 million for the first quarter compared to $10 million for the same period in 2024. The increase was primarily due to increased expenses related to legal and patent services, stock-based compensation and insurance, partially offset by a decrease in salaries and benefits.
As of March 31, 2025, Viking held cash, cash equivalents and short-term investments of $852 million, compared to $903 million as of the end of 2024.
&#8220;In the first quarter of 2025, Viking continued to build on the strong momentum achieved in 2024,&#8221; stated Brian Lian, Ph.D., CEO of Viking.
&#8220;Throughout the first quarter we continued to ramp up activities in support of the initiation of Phase 3 trials with the subcutaneous formulation of VK2735, which are on track to begin later this quarter. In addition, during the first quarter, we not only announced the initiation of the Phase 2 VENTURE-Oral Dosing trial evaluating the tablet formulation of VK2735, but also the completion of enrollment in this study,&#8221; Lian added.
VKTX Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Viking Therapeutics stock was down 1.12% after hours at $25.50 on Wednesday.&nbsp;&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

VKTX

Viking Therapeutics Stock Dips After Q1 EPS Miss: Details

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) saw its shares gain ground on Wednesday as optimism rose over a potential easing of<a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44935649/alibaba-nio-pdd-shares-rise-amid-potential-de-escalation-of-china-trade-tensions-whats-going-on" rel="noreferrer noopener"> trade tensions between the United States and China.</a>
During a closed-door event hosted by JPMorgan Chase &amp; Co. in Washington, U.S. Treasury Secretary Scott Bessent hinted at the possibility of a thaw in the current tariff standoff on Tuesday, which has cast a shadow over cross-border commerce.
Meanwhile, Nio's sub-brand Onvo made headlines at the 2025 Shanghai Auto Show by revealing its new flagship SUV, the L90.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44942792/tesla-q1-earnings-call-company-says-more-affordable-models-launching-this-year" rel="noreferrer noopener">Tesla Says More Affordable Models Launching This Year: ‘They Will Be Affordable And You'll Be Able To Buy One'</a>
Designed with space efficiency and family use in mind, the vehicle will hit the Chinese market later this year, CNeV Post <a target="_blank" href="https://cnevpost.com/2025/04/23/nio-onvo-unveils-l90-shanghai-auto-show/" rel="noreferrer noopener">reports</a>.
Onvo's L90 boasts generous dimensions — stretching over 5.1 meters long — and includes a wheelbase exceeding 3.1 meters.
The vehicle accommodates six passengers while still offering a trunk capacity for seven standard 20-inch suitcases. Additionally, the front trunk (frunk) features 240 liters of space, enough to stow away two large suitcases and a compact one, which Onvo says is currently unmatched in China.
Eric Yu, head of product at Onvo, underscored the L90's storage credentials, citing its market-leading frunk volume among SUVs available domestically, CnEV Post adds.
Meanwhile, William Li, Nio's founder and CEO, used the event to provide a detailed roadmap of the company's product pipeline for the year.
He confirmed that the revamped third-generation ES8 would debut in Q4, along with the unveiling of Onvo's next release — the L80 SUV, CnEV Post <a target="_blank" href="https://cnevpost.com/2025/04/23/nio-3rd-gen-es8-onvo-l80-q4/" rel="noreferrer noopener">reports</a>.
Nio plans to maintain a steady stream of product launches throughout 2025, ultimately reaching a total of nine models. These include the recently released ET9 luxury sedan and the compact Firefly, as well as updated versions of its ET5, ET5 Touring, ES6, and EC6 lines.
Price Action: NIO shares closed higher by 4.80% to $3.93&nbsp;on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/04/44965748/boeing-turns-in-solid-q1-but-analyst-flags-ongoing-delivery-hurdles" target="_blank" rel="noreferrer noopener">Boeing Turns In Solid Q1, But Analyst Flags Ongoing Delivery Hurdles</a></li>
</ul>
Photo by Tada Images via Shutterstock

What's Going On With Chinese EV Manufacturer NIO Stock On Wednesday?

Pacific Premier Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBI#NASDAQ">PPBI</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.30 by 23.33 percent. This is a 24.49 percent decrease over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $144.83 million which beat the analyst consensus estimate of $122.61 million by 18.13 percent. This is a 15.25 percent decrease over sales of $170.90 million the same period last year.

PPBI

Pacific Premier Bancorp Q1 GAAP EPS $0.37 Beats $0.30 Estimate, Sales $144.83M Beat $122.61M Estimate

Contracts

Montrose Environmental Group Wins $4M AUD Environmental Services Contract for Major Mining Operation in Australia

Barclays analyst Benjamin Budish maintains CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Equal-Weight and raises the price target from $279 to $283.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on CME Group, Raises Price Target to $283

INDA

President Trump Says There Is Direct Contact Between China and The U.S.; Says I Understand That India Will Reduce Tariffs

CB Financial Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBFV#NASDAQ">CBFV</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.43 by 16.28 percent. This is a 19.35 percent decrease over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $12.10 million which missed the analyst consensus estimate of $12.70 million by 4.74 percent. This is a 10.43 percent decrease over sales of $13.51 million the same period last year.

CBFV

CB Financial Services Q1 Adj. EPS $0.50 Beats $0.43 Estimate, Sales $12.10M Miss $12.70M Estimate

Across the recent three months, 14 analysts have shared their insights on Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $22.07, a high estimate of $29.00, and a low estimate of $19.00. Highlighting a 4.62% decrease, the current average has fallen from the previous average price target of $23.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1745445692_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Intel among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Matt Bryson &#x7C;Wedbush &#x7C;Lowers &#x7C;Neutral &#x7C; $19.00&#x7C;$20.00 &#x7C; 
&#x7C;Stacy Rasgon &#x7C;Bernstein &#x7C;Lowers &#x7C;Market Perform &#x7C; $21.00&#x7C;$25.00 &#x7C; 
&#x7C;Tom O'Malley &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $19.00&#x7C;$23.00 &#x7C; 
&#x7C;Christopher Rolland &#x7C;Susquehanna &#x7C;Lowers &#x7C;Neutral &#x7C; $22.00&#x7C;$24.00 &#x7C; 
&#x7C;Timothy Arcuri &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $22.00&#x7C;$23.00 &#x7C; 
&#x7C;Vivek Arya &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $25.00&#x7C;$19.00 &#x7C; 
&#x7C;Matthew Prisco &#x7C;Cantor Fitzgerald &#x7C;Raises &#x7C;Neutral &#x7C; $29.00&#x7C;$22.00 &#x7C; 
&#x7C;Harlan Sur &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $23.00&#x7C;$26.00 &#x7C; 
&#x7C;Ruben Roy &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $21.00&#x7C;$25.00 &#x7C; 
&#x7C;William Stein &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $21.00&#x7C;$22.00 &#x7C; 
&#x7C;Aaron Rakers &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $25.00&#x7C;$28.00 &#x7C; 
&#x7C;Matthew Prisco &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Neutral &#x7C; $22.00&#x7C;$22.00 &#x7C; 
&#x7C;Suji Desilva &#x7C;Roth MKM &#x7C;Lowers &#x7C;Neutral &#x7C; $20.00&#x7C;$25.00 &#x7C; 
&#x7C;Hans Mosesmann &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Sell &#x7C; $20.00&#x7C;$20.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intel. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Intel compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Intel's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Intel's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INTC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intel analyst ratings.</a>
<h2>About Intel</h2>
Intel is a leading digital chipmaker, focused on the design and manufacturing of microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and was the prime proponent of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. Intel has also been expanding into new adjacencies, such as communications infrastructure, automotive, and the Internet of Things. Further, Intel expects to leverage its chip manufacturing capabilities into an outsourced foundry model where it constructs chips for others.
<h3>Intel: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, Intel faced challenges, resulting in a decline of approximately -7.44% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Intel's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -0.88%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.13%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Intel's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.06%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Intel's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.5, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTC

A Glimpse Into The Expert Outlook On Intel Through 14 Analysts

During the last three months, 17 analysts shared their evaluations of Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Ncino, revealing an average target of $29.59, a high estimate of $42.00, and a low estimate of $19.00. Observing a downward trend, the current average is 24.69% lower than the prior average price target of $39.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1745445684_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Ncino among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brent Bracelin &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $25.00&#x7C;$28.00 &#x7C; 
&#x7C;Brad Sills &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $26.00&#x7C;$22.00 &#x7C; 
&#x7C;Ryan Tomasello &#x7C;Keefe, Bruyette &amp; Woods &#x7C;Lowers &#x7C;Outperform &#x7C; $28.00&#x7C;$40.00 &#x7C; 
&#x7C;Terry Tillman &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $21.00&#x7C;$44.00 &#x7C; 
&#x7C;Alexander Sklar &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $32.00&#x7C;$42.00 &#x7C; 
&#x7C;Aaron Kimson &#x7C;Citizens Capital Markets&#x7C;Lowers &#x7C;Market Outperform&#x7C; $32.00&#x7C;$43.00 &#x7C; 
&#x7C;Saket Kalia &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $24.00&#x7C;$44.00 &#x7C; 
&#x7C;Charles Nabhan &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $38.00&#x7C;$38.00 &#x7C; 
&#x7C;James Faucette &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $23.00&#x7C;$39.00 &#x7C; 
&#x7C;Adam Hotchkiss &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $24.00&#x7C;$42.00 &#x7C; 
&#x7C;Nick Altmann &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Perform &#x7C; $19.00&#x7C;$35.00 &#x7C; 
&#x7C;Mayank Tandon &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $28.00&#x7C;$45.00 &#x7C; 
&#x7C;Brent Bracelin &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $28.00&#x7C;$38.00 &#x7C; 
&#x7C;Ryan Tomasello &#x7C;Keefe, Bruyette &amp; Woods &#x7C;Lowers &#x7C;Outperform &#x7C; $40.00&#x7C;$44.00 &#x7C; 
&#x7C;Nick Altmann &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Outperform&#x7C; $35.00&#x7C;$42.00 &#x7C; 
&#x7C;Alexander Sklar &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $42.00&#x7C;$44.00 &#x7C; 
&#x7C;Charles Nabhan &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $38.00&#x7C;$38.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ncino. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Ncino compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ncino's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NCNO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ncino analyst ratings.</a>
<h2>Get to Know Ncino Better</h2>
Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes &amp; workflows and utilizes data analytics &amp; artificial intelligence that enables financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposits, and other accounts, and manage regulatory compliance. It also offers professional services, including configuration &amp; implementation, training, and advisory services. The company generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.
<h3>Understanding the Numbers: Ncino's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Ncino showcased positive performance, achieving a revenue growth rate of 14.29% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Ncino's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -13.16% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ncino's ROE stands out, surpassing industry averages. With an impressive ROE of -1.71%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.19%, the company showcases effective utilization of assets.
Debt Management: Ncino's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.22.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NCNO

Where Ncino Stands With Analysts

Throughout the last three months, 7 analysts have evaluated Integral Ad Science Holdi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $12.0, a high estimate of $17.00, and a low estimate of $7.00. Observing a downward trend, the current average is 13.85% lower than the prior average price target of $13.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1745445676_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Integral Ad Science Holdi among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mark Kelley &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $13.00&#x7C;$15.00 &#x7C; 
&#x7C;Raimo Lenschow &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $7.00&#x7C;$14.00 &#x7C; 
&#x7C;Matthew Cost &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $12.50&#x7C;$13.50 &#x7C; 
&#x7C;Vikram Kesavabhotla &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $9.00&#x7C;$16.00 &#x7C; 
&#x7C;Matthew Cost &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $13.50&#x7C;$13.00 &#x7C; 
&#x7C;Youssef Squali &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $17.00&#x7C;$16.00 &#x7C; 
&#x7C;Nat Schindler &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $12.00&#x7C;$10.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Integral Ad Science Holdi. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Integral Ad Science Holdi compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Integral Ad Science Holdi's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Integral Ad Science Holdi's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IAS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Integral Ad Science Holdi analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Integral Ad Science Holdi: A Closer Look</h2>
Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.
<h3>Integral Ad Science Holdi's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Integral Ad Science Holdi's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 13.96%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.
Net Margin: Integral Ad Science Holdi's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.98%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Integral Ad Science Holdi's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Integral Ad Science Holdi's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.34% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Integral Ad Science Holdi's debt-to-equity ratio is below the industry average at 0.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

7 Analysts Have This To Say About Integral Ad Science Holdi

Press Releases

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Collaborates with Multi Billion Dollar Clinical Development Player, Advancing Revolutionary Cancer Treatment Toward Clinical Trials

Alzamend Neuro

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

GT Biopharma

iBio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

MetaVia

Mainz Biomed

NuCana

Ocean Biomedical

Plus Therapeutics

Palatin Techs

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

SILO Pharma

Soligenix

Spruce Biosciences

Turnstone Biologics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

Silexion Therapeutics

Noticias

Últimas noticias sobre Silexion Therapeutics (NASDAQ:SLXN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL